Get The Free Sample Complete
SWOT & PESTLE Analysis Report
This report is shared in order to give you an idea of what the complete SWOT & PESTLE analysis report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals, at such affordable pricing.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get Your Free Summary Copy of the
SWOT & PESTLE Analysis Report
Get the summary SWOT & PESTLE.com report delivered straight to your email inbox for free. Our insightful and holistic reports have helped corporates, academia and researchers take their research forward. You also agree to receive email updates from us on our new reports and solutions.

Regeneron Pharmaceuticals SWOT & PESTLE Analysis

ID : 52791753| Oct 2020| 15 pages

COMPANY PROFILE -Regeneron

Business Sector :Biotech, Pharmaceuticals

Operating Geography :United States, North America, Global

About Regeneron :

Founded in 1988, Regeneron Pharmaceuticals is an American company in the biotech and pharmaceuticals space, headquartered in Tarrytown, New York. It was founded by Leonard S. Schleifer, MD, PhD who was an assistant professor at Cornell University Medical College and is also the current CEO of the company. In 1990, the company published its first paper which turned out to be the most highly cited neurobiology paper of the year. In 1991, it began trading its stock publicly on the NASDAQ (REGN). In 2000, the company began the clinical exploration of its first TRAP technology, ARCALYST (rilonacept) Injection. In 2003, it introduced its proprietary Veloci technologies through the publication of its first paper on VelociGene. In 2013, the company opened their first European business office in Dublin, Ireland. Through the years, it has also collaborated with players like Bayer and Sanofi for the production of their drugs outside the US. As of 2020, it has 7 commercial, in-house discovered medicines which have been approved by the FDA, namely – Arcalyst, Dupixent, Eylea, Kevzara, Libtayo, Praluent and Zaltrap- some of which are marketed by other leaders in the space. The company has 8,100 full-time employees as of December 2019. Apart from an office in Tarrytown, New York, the company has its facilities in Rensselaer, New York which is used for research, manufacturing, office and warehouse space.
Regeneron’s mission statement reads, “To use the power of science to bring new medicines to patients over and over again.”

Regeneron Revenue :


US$ 7,863.4 million – FY ended Dec 31st, 2019 (YoY growth of 17.1%)
US$ 6,710.8 million – FY ended Dec 31st, 2018

Competitive Analysis of Regeneron

SWOT
PESTLE
The SWOT analysis of Regeneron is presented below:
Strengths
Weaknesses
1. Clinical development of products in diverse disease areas
2. Advanced technological capabilities
3. Significant investment in R&D
4. Regeneron Genetics Centre – A wholly owned subsidiary of Regeneron
5. Robust strategic alliances and collaborations
6. Multiple titles awarded to the company in recent years
1. Heavy reliance on the success of the product Eylea
2. Dependence on a small number of customers
Opportunities
Threats
1. Adoption of multichannel strategy
2. Constant lookout for strategic alliances with other companies
1. Substantial competition from pharmaceutical, biotechnology and chemical companies
2. Sales of products dependent on other external factors
3. Commercialization of certain products depends on collaborations with other companies
4. Threat of imported products
SWOT & PESTLE (combined)
Complete Report
USD 12.53
*
  • with PayPal
  • with Debit/Credit card
Great quality, Affordable pricing.
Safe and secure payments
On purchase, the report will reach your email inbox within minutes. At rare times, a slight delay not exceeding 4 hours might be caused.

Detailed SWOT Analysis of Regeneron

 

Strength

1. Clinical development of products in diverse disease areas: Regeneron currently has seven products that have received marketing approval and also has 22 product candidates in clinical development across diverse disease areas. Their ability to develop product candidates is enhanced through their VelociSuite technology platforms. The cover broad medical areas like ophthalmology, immunology and inflammatory diseases, Oncology, cardiovascular/metabolic diseases, pain, infectious diseases, muscle diseases and disorders, bone and cartilage, neurobiology and diseases related to ageing.

2. Advanced technological capabilities in drug development: Scientists at Regeneron have developed two major technologies for the development of their products. The first is the Trap technology which fuses receptor components to the constant region of an antibody molecule to make a class of drugs they call "Traps". Eylea, Zaltrap and Arcalyst are drugs produced using this technology. The second technology is the VelociSuite platform which is used for discovering, developing and producing fully human antibodies. This platform consists of multiple technologies, namely- VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, and other related technologies, all of which serve different functions like development of antibodies, DNA manipulations and study, generation of genetically altered mice, screening of antibodies, generation of bi-specific antibodies and extending drug discovery capabilities respectively. This technology enables the company to increase the speed and efficiency of their early-stage drug development activities.

The remaining section of “Strength” is available only in the 'Complete Report' on purchase.

Weakness

This section is available only in the 'Complete Report' on purchase.

Opportunity

This section is available only in the 'Complete Report' on purchase.

Threat

This section is available only in the 'Complete Report' on purchase.

SWOT & PESTLE (combined)
Complete Report
USD 12.53
*
  • with PayPal
  • with Debit/Credit card
Great quality, Affordable pricing.
Safe and secure payments
On purchase, the report will reach your email inbox within minutes. At rare times, a slight delay not exceeding 4 hours might be caused.

Check Out Analysis of Other Relevant Companies

TABLE OF CONTENTS
DELIVERY AND FORMAT
WHY CHOOSE US?
How to Reference This Page?

You can use the following in your reference section in order to give credit to the source. For different referencing styles and detailed guidelines, please click here.

Regeneron Pharmaceuticals SWOT & PESTLE Analysis - SWOT & PESTLE.COM

SWOT & PESTLE.com (2020). Regeneron Pharmaceuticals SWOT & PESTLE Analysis - SWOT & PESTLE.com. [online] Available at: https://www.swotandpestle.com/regeneron/ [Accessed 28 Oct, 2020].

In-text: (SWOT & PESTLE.com, 2020)

Copyrights and Disclaimer

Regeneron SWOT and PESTLE analysis has been conducted by Saurabh Dewangan and reviewed by senior analysts from Barakaat Consulting.

Copyright of Regeneron SWOT and PESTLE Analysis is the property of Barakaat Consulting. Please refer to the Terms and Conditions and Disclaimer for usage guidelines.

You might also like to check out :
Regeneron Pharmaceuticals SWOT & PESTLE Analysis
Price : USD 12.53